Insiders · TARS

TARS insider transactions

Tarsus Pharmaceuticals Inc. (TARS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for TARS

• 40d
  Director Pyott David E I converted options into 1,383 shares (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 75d
  SEC Form 4 filed by Neervannan Seshadri

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Whitfield Dianne C.

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Wahl Bryan

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Neervannan Seshadri

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Mottiwala Aziz

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Lin Elizabeth Yeu

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Farrow Jeffrey S

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 80d
  SEC Form 4 filed by Azamian Bobak R.

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 81d
  SEC Form 4 filed by Link William J Phd

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  Chief Human Resources Officer Whitfield Dianne C. converted options into 23,909 shares, increasing direct ownership by 102% to 47,302 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  General Counsel Wahl Bryan converted options into 24,236 shares, increasing direct ownership by 46% to 76,399 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  Chief Operating Officer Neervannan Seshadri converted options into 26,287 shares, increasing direct ownership by 37% to 97,104 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  Chief Commercial Officer Mottiwala Aziz converted options into 26,482 shares, increasing direct ownership by 55% to 74,536 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  Officer Farrow Jeffrey S converted options into 13,042 shares, increasing direct ownership by 36% to 49,746 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  President/CEO and Board Chair Azamian Bobak R. converted options into 66,274 shares, increasing direct ownership by 3,787% to 68,024 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 82d
  Chief Medical Officer Lin Elizabeth Yeu converted options into 2,511 shares, increasing direct ownership by 11% to 24,452 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by General Counsel Wahl Bryan

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by Officer Farrow Jeffrey S

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by Chief Commercial Officer Mottiwala Aziz

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by Chief Human Resources Officer Whitfield Dianne C.

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by Chief Operating Officer Neervannan Seshadri

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by President/CEO and Board Chair Azamian Bobak R.

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 90d
  SEC Form 4 filed by Chief Medical Officer Lin Elizabeth Yeu

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 94d
  Chief Operating Officer Neervannan Seshadri sold $641,421 worth of shares (8,366 units at $76.67), decreasing direct ownership by 11% to 70,817 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 107d
  SEC Form 4 filed by Director Pyott David E I

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 107d
  New insider Pyott David E I claimed ownership of 7,991 shares (SEC Form 3)

  3 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 144d
  Director Goodrich Katherine converted options into 2,233 shares (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 152d
  Chief Human Resources Officer Whitfield Dianne C. sold $1,255,684 worth of shares (15,565 units at $80.67), decreasing direct ownership by 40% to 23,393 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 159d
  President/CEO and Board Chair Azamian Bobak R. sold $495,089 worth of shares (6,000 units at $82.51) (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 171d
  Chief Operating Officer Neervannan Seshadri gifted 950 shares and received a gift of 475 shares, decreasing direct ownership by 1% to 79,183 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 171d
  Chief Human Resources Officer Whitfield Dianne C. sold $592,500 worth of shares (7,397 units at $80.10), decreasing direct ownership by 16% to 38,958 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 172d
  Director Link William J Phd sold $1,864,678 worth of shares (22,946 units at $81.26), decreasing direct ownership by 9% to 128,832 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 172d
  Chief Medical Officer Lin Elizabeth Yeu converted options into 6,819 shares and sold $165,201 worth of shares (2,078 units at $79.50), increasing direct ownership by 28% to 21,941 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 181d
  President/CEO and Board Chair Azamian Bobak R. gifted 51,885 shares (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 254d
  President/CEO and Board Chair Azamian Bobak R. sold $332,220 worth of shares (6,000 units at $55.37) (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 262d
  Director Link William J Phd gifted 2,000 shares, decreasing direct ownership by 1% to 141,332 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 264d
  Director Morrison Scott W converted options into 1,334 shares, increasing direct ownership by 40% to 4,684 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 270d
  Director Link William J Phd sold $1,545,612 worth of shares (27,116 units at $57.00), decreasing direct ownership by 16% to 143,332 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 298d
  President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 354d
  Officer Farrow Jeffrey S converted options into 27,881 shares and sold $550,035 worth of shares (13,608 units at $40.42), increasing direct ownership by 64% to 36,704 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 355d
  Chief Medical Officer Lin Elizabeth Yeu converted options into 3,350 shares and sold $41,326 worth of shares (1,006 units at $41.08), increasing direct ownership by 44% to 7,694 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  Director Chaudhuri Bhaskar converted options into 3,350 shares, increasing direct ownership by 63% to 8,700 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  SEC Form 4 filed by Director Goodrich Katherine

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  Director Goldberg Andrew D. converted options into 3,350 shares, increasing direct ownership by 25% to 16,700 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  Director Yarno Wendy L converted options into 3,350 shares, increasing direct ownership by 32% to 13,700 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  Director Morrison Scott W converted options into 3,350 shares (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 356d
  Director Link William J Phd converted options into 3,350 shares, increasing direct ownership by 2% to 170,448 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 361d
  Chief Commercial Officer Mottiwala Aziz sold $765,800 worth of shares (17,500 units at $43.76), decreasing direct ownership by 27% to 47,557 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 438d
  President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  Chief Commercial Officer Mottiwala Aziz sold $505,856 worth of shares (10,565 units at $47.88), decreasing direct ownership by 14% to 65,057 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  Chief Operating Officer Neervannan Seshadri sold $363,142 worth of shares (7,583 units at $47.89), decreasing direct ownership by 9% to 79,682 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  General Counsel Wahl Bryan sold $463,766 worth of shares (9,686 units at $47.88), decreasing direct ownership by 16% to 51,712 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  Chief Human Resources Officer Whitfield Dianne C. sold $321,323 worth of shares (6,711 units at $47.88), decreasing direct ownership by 13% to 46,355 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  President/CEO and Board Chair Azamian Bobak R. sold $1,163,050 worth of shares (24,216 units at $48.03), decreasing direct ownership by 31% to 53,635 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 444d
  Officer Farrow Jeffrey S sold $178,306 worth of shares (3,724 units at $47.88), decreasing direct ownership by 14% to 22,431 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 446d
  Officer Farrow Jeffrey S converted options into 8,019 shares, increasing direct ownership by 44% to 26,155 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 446d
  President/CEO and Board Chair Azamian Bobak R. converted options into 51,395 shares, increasing direct ownership by 194% to 77,851 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 446d
  Chief Human Resources Officer Whitfield Dianne C. converted options into 18,885 shares, increasing direct ownership by 55% to 53,066 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
• 446d
  General Counsel Wahl Bryan converted options into 19,213 shares, increasing direct ownership by 46% to 61,398 units (SEC Form 4)

  4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)